Format

Send to

Choose Destination
Oncoimmunology. 2015 Feb 3;4(5):e1005448. eCollection 2015 May.

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Author information

1
Georgia Regents University, Cancer Center ; Augusta, GA, USA.
2
Georgia Regents University, Cancer Center ; Augusta, GA, USA ; bluebird bio ; Cambridge, MA, USA.
3
Georgia Regents University, Cancer Center ; Augusta, GA, USA ; Duke University ; Durham, NC, USA.

Abstract

The CD8 + T-cell response comprises terminally differentiated effector cells and antigen-experienced memory T cells. The latter encompass central (TCM) and effector (TEM) memory cells. TCM cells are superior in their protection against viral and bacterial challenges and mediation of antitumor immunity due to their higher proliferative ability upon antigen re-encounter. Defining a mechanism to enhance TCM cells and delay terminal differentiation of CD8 + T cells is crucial for cancer immune therapy, as it can promote a better tumor immune response. The differentiation of CD8 + memory T cells is thought to be coordinated by the phosphoinositide 3-kinase (PI3K)/Akt pathway. We, therefore, investigated the role of Akt isoforms in the differentiation and proliferation of memory CD8 + T cells. We found that Akt1 and Akt2, but not Akt3, drive the terminal differentiation of CD8 + T cells, and their inhibition enhances the therapeutically superior TCM phenotype. Furthermore, the inhibition of Akt1 and Akt2, but not Akt 3, delays CD8 + T-cell exhaustion and preserves naïve and TCM CD8 + T cells, thus enhancing their proliferative ability and survival and prolonging their cytokine and Granzyme B production ability. Here, we define a mechanism in which proliferative potential, function, and survival of CD8 + T cells are enhanced by maintaining a reservoir of TCM and naïve cells using only Akt1 and Akt2 inhibition. Therefore, our findings strongly suggest the utility of using Akt1 and Akt2 inhibitors to modulate CD8 + T cells, both for adoptive cell transfer and vaccine-based cancer immune therapies.

KEYWORDS:

ACT, adoptive cell transfer; Akt; CBA, cytometric bead array; IFNγ, interferon gamma; KLRG-1, killer cell lectin-like receptor subfamily G member 1; KO, knockout; SORP, special order research product; T cells; TCM, central memory; TCR, T-cell receptor; TEM, effector memory; TNF, tumor necrosis factor; Tregs, regulatory T cells; VCT, violet cell trace; WT, wild type; central memory; effector memory; proliferation

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center